Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme.
Todd A HardyP AouadMichael Harry BarnettStefan BlumSimon A BroadleyW M CarrollD CrimminsD GriffithsS HodgkinsonJ Lechner-ScottA LeeR MalhotraP McCombeJ ParrattC PlummerAnneke Van Der WaltK MartelR A WalkerPublished in: Multiple sclerosis journal - experimental, translational and clinical (2024)
Despite the limitations of self-reported data and the challenges of the COVID-19 pandemic, this study provides insights into siponimod onboarding in Australia and demonstrates the positive impact of care partner support.
Keyphrases
- multiple sclerosis
- end stage renal disease
- ejection fraction
- healthcare
- chronic kidney disease
- newly diagnosed
- palliative care
- peritoneal dialysis
- randomized controlled trial
- quality improvement
- electronic health record
- pain management
- chronic pain
- human immunodeficiency virus
- men who have sex with men
- hiv testing
- double blind